SCHEMBL1158434

SCHEMBL1158434

Cc1ccnc(Nc2cc3ccn(C)c(=O)c3c(NC[C@H]3CCCO3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 5/20 0.47
▸ ALDH1A1 P00352 6/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ KDM4E B2RXH2 4/20 0.40
▸ HPGD P15428 4/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ KLK7 P49862 1/20 0.39
▸ UTS2R Q9UKP6 1/20 0.38
▸ TNK2 Q07912 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158318 0.91 SYK (0.47) SYKALDH1A1NPC1RAB9AKDM4E
SCHEMBL1158761 0.88 SYK (0.46) SYKALDH1A1HPGDHSD17B10ALOX15
SCHEMBL1158888 0.88 SYK (0.46) SYKALDH1A1HPGDHSD17B10ALOX15
SCHEMBL12796051 0.88 SYK (0.46) SYKALDH1A1HPGDHSD17B10ALOX15
SCHEMBL12797891 0.86 SYK (0.43) SYKALDH1A1NPC1RAB9ATDP1
SCHEMBL1158282 0.83 FER (0.42) SYKALDH1A1NPC1RAB9ATDP1
SCHEMBL1158658 0.83 FER (0.42) SYKALDH1A1NPC1RAB9ATDP1
SCHEMBL12797887 0.82 SYK (0.42) SYKTNK2
SCHEMBL1158505 0.80 SYK (0.51) SYKNPC1RAB9A
SCHEMBL1158410 0.80 SYK (0.62) SYKALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 — — EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 — — EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885ALDH1A1 4436/4885NPC1 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback